NIPT Focus Ravgen specializes in non-invasive prenatal genetic testing and fetal DNA analysis from maternal blood, presenting a clear cross-sell potential to obstetric clinics, IVF centers, and maternal-fetal medicine practices looking to expand their diagnostic offerings.

Paternity Expansion In addition to prenatal diagnostics, Ravgen offers paternity testing using non-invasive samples, suggesting opportunities to partner with fertility clinics, family planning centers, and postnatal labs seeking non-invasive, quick turnaround options.

Strategic Partnerships Recent collaboration with TestSource Lab indicates openness to distribution and lab service partnerships; leverage similar alliances to scale testing capacity, geographic reach, and service diversity.

Patent and IP Position Ravgen's history of patent-related litigation against Illumina signals a strong IP portfolio; consider value propositions around licensing discussions, collaboration on validated methods, and risk mitigations for potential distributors.

Market Readiness With modest headcount but substantial revenue range and proximity to major diagnostics ecosystems, there is a path for channel sales through clinical distributors, direct-to-lab services, and integration with existing lab management platforms.